Surprisingly, endostar, an modified endostatin bearing a 6His zinc-binding peptide at its N-terminus, shows more potent clinical effectiveness than rhEndostatin, and has been approved by the State Food and Drug Administration of China (SFDA) as a cancer drug. The gene discussed is COL18A1; the disease is cancer.